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Background: Diagnostic analysis of patients with developmental disorders has improved over recent years largely
due to the use of microarray technology. Array methods that facilitate copy number analysis have enabled the
diagnosis of up to 20% more patients with previously normal karyotyping results. A substantial number of patients
remain undiagnosed, however.
Methods and Results: Using the Genome-Wide Human SNP array 6.0, we analyzed 35 patients with a
developmental disorder of unknown cause and normal array comparative genomic hybridization (array CGH) results,
in order to characterize previously undefined genomic aberrations. We detected no seemingly pathogenic copy
number aberrations. Most of the vast amount of data produced by the array was polymorphic and non-informative.
Filtering of this data, based on copy number variant (CNV) population frequencies as well as phenotypically relevant
genes, enabled pinpointing regions of allelic homozygosity that included candidate genes correlating to the
phenotypic features in four patients, but results could not be confirmed.
Conclusions: In this study, the use of an ultra high-resolution SNP array did not contribute to further diagnose
patients with developmental disorders of unknown cause. The statistical power of these results is limited by the
small size of the patient cohort, and interpretation of these negative results can only be applied to the patients
studied here. We present the results of our study and the recurrence of clustered allelic homozygosity present in
this material, as detected by the SNP 6.0 array.
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The diagnostic yield of microarray comparative genomic
hybridizations (array CGH) has already proven to exceed
that of cytogenetic methods, except when it comes to
balanced rearrangements. A consensus statement sug-
gests that microarrays should be used as the first line of
testing for developmental disorders of unknown cause
[1]. However, as our previous study shows, approxi-
mately 80 % of patients with a developmental disorder of
unknown cause (mental retardation and/or malformations* Correspondence: linda.siggberg@helsinki.fi
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reproduction in any medium, provided the orand/or neurological disorders) remain undiagnosed even
by array CGH analysis (44 K, 180 K, or 244 K) [2]. Thus,
other methods are clearly needed to define the pathogenic
mechanisms. It is plausible that small copy number var-
iants (CNVs) may go undetected if the probe coverage is
limited, as it may be in low-resolution arrays. By increas-
ing the resolution, one would thus expect to detect in-
creasingly smaller pathogenic CNVs.
The frequency of uniparental disomy (UPD) in new-
borns is reportedly ~0.029% [3]. Around 1,100 cases of
whole chromosome UPD and some 120 reports on
segmental UPD are described in the literature [4].
Some recessive diseases are expressed in children who
have inherited the mutation form a single carrieral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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very early mitotic recombination event between paren-
tal homologous chromosomes causing segmental UPD
of the genomic segment containing the mutation, and
thereby causing a reduction to homozygosity.
As the market is flooded with new arrays, most having
an increased resolution and a promise of ever higher de-
tection rates, the question remains what the added value
is of these ultra-high resolution arrays. To test this, we
used an array with 1.8 million probes and an average
resolution of 0.7Kb to analyze samples of 35 patients
with developmental disorder of unknown cause, normal
karyotype, and normal array CGH results by use of Agi-
lent 44 K, 180 K, or 244 K platforms (Agilent Technolo-
gies, Santa Clara, CA, USA).Methods
Participants
Patients with previous normal array CGH results were
asked to participate in the project. All 35 patients were
Finnish of origin and had mild to severe mental retard-
ation, associated with dysmorphic features and/or con-
genital anomalies (Table 1). In addition, 16 patients also
had epilepsy. For diagnostic purposes patients had previ-
ously been analyzed by whole-genome array CGH
(Human Genome CGH Microarray, Agilent Technolo-
gies, Santa Clara, CA); 20 using the 244 K platform, 8
using a 180 K platform, and 7 using a 44 K platform.
Informed consent was given by all participating families.
Blood samples were collected from all patients and their
parents. Ethical permission for this project was given by
the Ethics Review Board of Helsinki and Uusimaa Hos-
pital District.SNP array
DNA was extracted from blood samples according to
standard protocols. Analysis by the Genome-wide
human SNP array 6.0 was performed according to
manufacturer protocols (Affymetrix, Santa Clara, CA,
USA). In short; DNA was digested, ligated to adapters,
and amplified by PCR. Samples were purified using mag-
netic beads and further fragmented and labelled with
biotin. After hybridization arrays were washed and
stained with streptavidin and anti-streptavidin antibodies
and finally the arrays were scanned using the Affymetrix
GeneChip scanner.Analysis
Data was extracted from the scanned image using the
Genotyping console software V.3.0.2, creating a CEL file.
Areas containing CNVs and allelic homozygosity were
detected using the Hidden-Markow-Model. Theresulting data was analyzed using the Chromosome Ana-
lysis Suite software V.1.0.
Reference data
Data was extracted by comparison to a reference data
set established from 90 Caucasian individuals, which had
previously been analyzed using the SNP 6.0 array in the
HapMap project (www.hapmap.org). As an additional
in-house reference set, we used results of 54 individuals
studied using the SNP 6.0 array, whereof 19 healthy nor-
mal relatives of the patients, and 35 unrelated patients
with an unexplained developmental disorder. Sample
identities were kept anonymous and the information was
only used for reference purposes. These in-house refer-
ence sets were used to filter out polymorphic changes in
the patient data studied here.
Selected CNVs of the patients were compared to a
Finnish population cohort [6]. This population cohort
data consist of CNVs detected, using whole-genome
SNP analysis, in 2163 healthy Finnish individuals with
PennCNV [7]. In the population data, low quality sam-
ples (N = 98) with Log R Ratio standard deviation of
probe signal intensities > 0.35 or > 115 CNV calls were
excluded. Only CNVs with three or more probes were
included in the final population data. CNV calls of the
study samples were clustered into CNV regions when in-
dividual CNVs overlapped by one or more base pairs.
Filtering relevant CNVs and potential UPDs
The first set of default filtering marked all duplications
and deletions ≥0.7Kb and all allelic homozygosities
≥100Kb containing at least 10 markers to be included.
This was based on the theoretical resolution of the array
being 0.7Kb, in addition to information from the Hap-
Map phase 1 study showing that approximately 70% of
common haplotype blocks are ≤100Kb [8] . Allelic
homozygosity was called by the analysis software where
there was a stretch of homozygous SNPs in a chromo-
somal segment.
The second filtering was based on the comparison of
all aberrations detected in the patients of this study
(N= 35), an in-house patient reference set (N= 35) and
an in-house normal reference set (N = 19) as well as the
database of genomic variants (DGV) [9]. Aberrations of
one patient that were not present in any of the other
groups (potentially “unique”) were further processed by
studying their genetic content and association to dis-
eases and traits, as stated in publications or OMIM, and
whether these correlated to the patient’s phenotype. If
this did not yield a candidate aberration, all aberrations
of a patient were reviewed based on only the associated
OMIM disease, despite the frequency of similar changes
in the reference sets. The CNVs that were picked out as
potential candidates were further compared to CNV data
Table 1 Clinical characteristics of patients studied
P. Nr. Growth Head and
neck
Eyes and vision Ears and
hearing
Face Cardiovascular Genitourinary Skeletal and
limb defects
Neurologic Other
1. Obesity Astigmatism Postaxial
polydactyly
(one foot) Short
meta-carpals
V finger
clino-dactyly
ID Hypotonia Bardet-Biedl
suspected
2 Severe DD
No walk/crawl
No speech
Epilepsy Drooling
3. Dolicocephaly
Narrow,
prominent
forehead Low,
uneven
hairline
Epichantal folds DD Abnormal
pons
Hemangiomas
4. Short stature Low nasal bridge Horseshoe
kidney Anal
atresia
Small hands
and feet
ID Balanced t(X;13)
(q28;q12)
5. Simple ears Thick and straight
eyebrows Broad
nasal bridge
Long philtrum
Retrognathia
Autism ID Epilepsy
6. Short stature Microcephaly Blindness Optic
nerve hypoplasia
Scoliosis ID Epilepsy Severe
hypotonia
7. Hydrocephalus Brain malformation
Severe DD
8 Microcephaly Hypertelorism Small nose Low
nasal bridge
Tented upper lip
Severe DD
Severe epilepsy
ATRX suspected
9. Severe optic
atrophy Impaired
vision
ID Epilepsy Cortical
atrophy
10. Mild hypertelorism Low-set ears Triangular face
Small jaw High
palate Thin upper
lip
Hyper-extensible
joints
ID Autistic features
Intractable epilepsy
Frax-dna, SCN1A,
CLN8 4p-FISH
normal
11. Upslanting
palpebal
fissures
Large
earlobes
Small jaw Clubfoot ID Autistic features
Intractable epilepsy
12. Epichantic folds Flat face Tapering fingers
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Table 1 Clinical characteristics of patients studied (Continued)
Large
earlobes
ID Autistic features
ADHD
Balanced t(2;9)
(q13q22.3)
de novo
13. Macrocephaly Severe ID Hypotonia
Autism Epilepsy
Inv 2(p13p25)
mat., DMPK
mutation
negative
14. Severe myopia
Cataracta
Synophrys Curved
eyebrows
Upturned
pinched nose Big
mouth Full lips
Atrial septum
defect
Severe DD Epilepsy
15. Microcephaly Impaired vision Ventricular
septum defect
Epilepsy DD
16. ID Beahvioural
disturbances Autism
No malformation
or dysmorphism
17. ID DD
18. Growth
retardation
Hypertelorism Mild ventricular
septum defect
ID
19. &
20.
DD No structural
defects
21 Microcephaly Strabismus Missing lobuli Small nose Low
nasal bridge
Smooth philtrum
Thin lips
Proximal
thumbs
Pes planus
ID Intractable
epilepsy Ataxia
22. Pre- and postnatal
growth retardation
Broad nasal root
Short nose Bifid
nasal tip
Cryptorchidism
Hypoplastic
scrotum
Scoliosis
Syndactylies
Slow motor
development
Hypotonia Expressive
language disorder
Congenital
contractures
Dimples
23. Mild dysmorphism ID Epilepsy
24. Microcephaly Hypertelorism
Epicanthic folds
Disorder of
visual cortex
Low-set and
posteriorly
rotated ears
Micrognathia Cleft
palate
ID Epilepsy
Hypoplastic
cerebellar
vermis
Monozygotic
twin, twin
sister healthy
25. Tall stature
Advanced bone
age
Deep set eyes
Hypotelorism
Epicanthic folds
Strabismus
Short nose
Anteverted nares
Tented upper lip
Cryptorchidism ID No speech
Autism
Glypican-3 and
PHF6 mutation
analyses negative
26. Short stature ID Intractable
epilepsy Tremor
Myoclonias Distal
spasticity
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Table 1 Clinical characteristics of patients studied (Continued)
27. Small for
Gestational Age
Downslanting
palpebral fissures
Strabismus
Frontal bossing Exostosis
(familial)
Broad hallux
Overriding toes
Scoliosis
ID Epilepsy Inguinal hernia
28. Downslanting
palpebral fissures
Hearing
impairment
Coarse hair Thick
eyebrows Thick
lips Malposition
of teeth
Hypertrophic
cardiomyopathy
Hip
dis-placement
Long thin bones
Normal
intelligence
29. Epilepsy ID
Alternating
hemiplegia
of childhood
30. Small for
gestational age
Prematurity Short
stature
Microcephaly Severe myopia
Coloboma of
papillae Optic
atrophy
Nystagmus
Strabismus
High palate
Gum hypertrophy
Coarctation of
aorta
Inguinal hernia ID Intractable
epilepsy Hemiparesis
(peri-ventricular
leukomalacia)
31. Central blindness
Nystagmus
ID Intractable
epilepsy Hypotonia
Distal spasticity
32. Short stature Normal
development
Vomiting
Feeding
difficulties
33. Neck fistula Dysmorphic
malocclusion
of teeth
Uni-ventricular
heart
Brain atrophy
Epilepsy
Simian-crease
Sinus pilonidalis
34. ID Intractable
epilepsy Hypotonia
Distal spasticity
35. Dolicocephaly Epichantic fold Simple ears Thin upper-lip
Long philtrum
Broad nasal
bridge
ID Arnold Chiari
malformation
The table presents the clinical characteristics of the 35 patients studied. DD=developmental delay, ID = intellectual disability.
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rations that were present in less than 50 individuals of
the Finnish population cohort were initially considered
as potentially pathogenic.
Validation of candidate aberrations
Only aberrations that were considered to potentially as-
sociate with patient’s phenotype were attempted
validation.
Microsatellite marker analysis
Potential segmental UPDs were analyzed by microsatel-
lite marker analysis (chr15: D15S204, D15S124; chr6:
D6S468, D6S2418; chr11: D11S4140; chr17: D17S578,
D17S1832, D17S1828).
The markers were selected based on their location,
and on information that they are highly polymorphic in
the Caucasian population. Fragments were labelled with
a fluorescent HEX label, and separated on an Applied
Biosystem 3730XL (Life Technologies, Carlsbad, CA,Figure 1 Frequency of CNVs and allelic homozygosity. The figure visua
regions of allelic homozygosity (LOH) in 70 patients (patients of this study
disorders of unknown cause as seen by the Integrative Genomics Viewer (I
vertical bars show the percentage of patients that have a CNV in a particul
percentage, thus indicating as CNP.USA) capillary electrophoresis instrument, according to
manufacturer recommendations. Genotypes were called
using Applied Biosystems GeneMapper 3.7 software.
Results
The immense amount of data created by the Genome-
wide human SNP array 6.0 warrants filtering for clear
interpretation. The Genotyping Console software identi-
fied between 200–1000 changes per patient (Figure 1),
depending on the technical quality of the result. More
changes were detected in samples with lesser quality.
After filtering, based on the uniqueness of the CNVs or
regions of homozygosity compared to the references,
each patient presented 8–20 unique changes (≥90%
CNVs) on average. In samples with lesser quality, ≥100
unique changes were detected. Further research on gene
content and phenotypes previously mapped to these
regions revealed 23 CNVs and 28 regions of homozygos-
ity that putatively correlated with the clinical phenotype
in 26 patients. Nine patients had no CNVs or regions oflizes the frequency of copy number changes (loss and gain) and
N= 35 and the in-house reference set N = 35) with developmental
GV) software V.1.5 (The Broad Institute, Cambridge, MA, USA). The
ar area of a chromsome. The higher the bar, the higher the
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associate with a disease that correlated with the patient’s
phenotype, and their results were thus considered nor-
mal. The associated phenotypes related to the aberration
found in 26 patients were further evaluated by the
patients’ clinicians, and the frequencies of the observed
CNVs were monitored in the Finnish population cohort
(n = 2,065). As a result, in four patients, a region of al-
lelic homozygosity was considered a potential candidate
for causation of their clinical state (Table 2). No CNVs
were considered candidates after clinical evaluation.
We further attempted verification of four potential
segmental UPDs by microsatellite marker analysis. In all
the four cases we observed two distinct alleles with at
least some of the more informative multiallelic markers,
suggesting that the observed LOHs were most probably
caused by the same allelic SNP haplotypes being inher-
ited from both the parents (Table 2).
Further comparison, of all patient SNP array data to
the normal data from unaffected individuals, revealed 21
regions of clustering (≥40 % frequency) of allelic homo-
zygosity to specific locations of the genome (Table 3).
However, no significant differences were detected be-
tween the frequencies of clustered regions in patients
and the unaffected relatives in this small set of samples.Discussion
In our previous study of 150 patients with developmen-
tal disorders of unknown cause and a normal karyotype,
we were able to identify a (potential) causative aberra-
tion in 18% of the patients, by using a 44 K or 244 K
array CGH platform [2].Table 2 Results from microsatellite marker analysis
Patient Chromosome location Marker Location start Location
1 15q23q24.1 D15S204 72300758 72300879
D15S124 73092468 73092572
17 6q16.3 D6S468 101630330 101630479
D6S2418 101352425 101352639
32 11q13.4 DS11S4140 71945684 71945874
28 17p13.2p13.1 D17S578 6824007 6824153
D17S1832 5972677 5972867
D17S1828 3810467 3810673
The table presents the results of microsatellite marker analysis of 4 patients and the
thus exclude segmental UPD. The numbers in the patient/mother/father column re
one marker from each parent.To determine whether, by increasing the resolution,
any additional copy number changes or regions of UPD
could be detected, we studied 35 patients with a normal
array CGH result.
Allelic homozygosity is typically caused by linkage and
co-segregation of certain blocks of DNA, termed haplo-
types [8]. In a small founder population, such as the
Finnish population, the founder effect increases the like-
lihood that the parents will have the same haplotype,
and is as such not a segmental UPD [10]. True segmen-
tal UPD is typically due to a duplication in one chromo-
some and a reciprocal deletion in the other; or the
fertilization of a disomic and monosomic gamete, som-
atic crossing over and subsequent trisomic rescue [11].
If the genomic segment harbours a recessive mutation,
which subsequent to UPD will be present in two copies
(reduction to homozygosity), it causes a recessive dis-
ease. Equally relevant, the segment can be preferentially
imprinted, causing complete silencing, which is the
equivalent of a deletion. Such presentations of recessive
syndromes that are inherited from one normal parent
are known in some 40 patients [12].
We were interested to see whether the regions of al-
lelic homozygosity detected by the SNP array were in
fact segmental UPDs and associated with an autosomal
recessive disease. We were, however, unable to confirm
these results and thus the SNP array did not yield more
molecular diagnoses in this study of developmental dis-
orders of unknown cause. This may be due to the fact
that all patients had previously been studied by another
high-resolution array, with 8.9Kb (244 K), 13Kb (180 K),
and 35Kb (44 K) theoretical resolutions. Although sev-
eral new CNVs, previously undetected by the array CGHstop Patient Mother Father Associated OMIM
disease (gene)
123/123 123/125 123/125 MIM #209900, Bardet-Biedl
Syndrome (BBS4)
104/106 106/106 104/106
155/159 159/159 155/155 MIM #611092, Mental
retardation (GRIK2)
222/230 222/248 230/238
195/195 195/197 195/197 MIM #270400,
Smith-Lemli-Opitz
syndrome (DHCR7)
173/173 173/173 155/173 MIM #201475, AcylCoA
dehydrogenase deficiency
(ACADVL)
173/185 173/185 171/173/185/193
220/220 214/220 214/220
ir parents, suggesting biparental inheritance of the genomic segment, and
present the two markers detected. In all cases, the patient has likely inherited
Table 3 Regions of clustered allelic homozygosity
Chromosome Band Appoximate range (Kb) Frequency patients (n = 70) Frequency normals (n = 19)
1 p33-p32.3 48 700–53 300 47.7% 47.7%
1 q21.1-q21.2 145 800–148 500 49% 50%
2 q21.2-q21.3 134 334–136 693 42% 58%
3 p21.31-p21.1 46 500–52 500 71% 68%
4 p15.1 31 838–34 524 60% 57%
8 q22.2 99 200–101 200 47% 63%
8 p11.21-p11.1 41 870–43 270 49% 47%
8 q11.1-q11.21 47 040–49 000 46% 68%
10 p11.21 36 720–38 490 43% 31%
10 q22.2-q22.2 73 200–76 460 44% 31%
12 q21.32-q21.33 85 850–89 100 47% 47%
12 q24.11-q24.13 108 600–111 600 55% 68%
14 q23.3-q24.1 65 500–67 100 62% 73%
15 q12-q13.1 25 400–27 200 71% 68%
15 q15.1-q21.1 40 100–43 730 64% 84%
15 q23-q24.1 69 300–71 700 41% 15%
16 p11.2-p11.1 33 394–34 550 62% 68%
16 q11.2-q12.1 45 092–47 450 64% 63%
16 q21-q22.1 64 850–67 100 48% 57%
17 q22-q23.2 54 610–56 850 67% 68%
20 q11.22-q11.23 31 910–35 500 68% 42%
The table presents the frequency (> 40%) of clustered regions of allelic homozygosity in the patient cohort (n = 70, including in-house reference) compared to the
unaffected relatives (n = 19). Kilobase range according to Genome build 19 (NCBI 37).
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detected, the pathogenic relevance of these changes were
considered insignificant in correlation to the patient’s
phenotype. It is, however, possible that changes dis-
missed in this study are pathogenic by means of span-
ning genomic segments that do not directly involve
disease genes, but rather their regulatory elements.
Our results differ from previously published studies
using similar research settings. Bernardini et al. (2010),
using the SNP 6.0 array platform with a 75Kb cut-off
value for detected CNVs, reported potentially pathogenic
CNVs in 6% of patients with normal array CGH result
(44 K) [13]. Mannik et al. (2010), using another SNP
array with a 50Kb resolution, reported a 23% detection
rate in patients with a normal karyotype [14]. Bernardini
et al. and Mannik et al. had higher detection rates than
this study; perhaps as their first-line of array analysis
was, at least partly, done by a lower-resolution method
(35Kb and 50Kb respectively) compared to the first-line
of detection in this study (8,9Kb, 13Kb and 35Kb). Also,
it is important to note that the statistical power is lim-
ited by the small size of our patient cohort, and thus
results are not entirely comparable with Bernardini and
Mannik’s.
UPDs have not been reported in either of the above
mentioned studies. However, in a study of 117 patientswith a normal karyotype analysed using the 250 K SNP
array (Affymetrix, Santa Clara, CA, USA), pathogenic
CNVs were detected in 18 patients, and potentially
pathogenic segmental UPDs ≥5 Mb in 5, verified by
microsatellite marker analysis [15]. The presence of
UPDs was also evaluated in another study of 120
patients, using a 500 K SNP array platform [16]. In that
study they were unable to verify UPD in any of 121
detected regions of homozygosity in 72 patients with de-
velopmental disorder of unknown cause. In addition, in
a study of 100 patients with developmental disorder,
using a 500 K SNP array, two patients were found to
have UPD, the clinical significance of which remained
unclear [17]. Thus, UPDs are detectable using SNP
arrays, but their clinical significance is difficult to
interpret.
Conclusions
Although there is a clear added value of high-resolution
arrays in various fields of genetics, it seems that there is
a limit to how much the yield can be increased by in-
creasing the theoretical resolution of the analysis plat-
form. Despite the fact that the SNP array has increased
probe spacing compared to the 44 K, 180 K, and 244 K
array, and is able to detect more CNVs and regions of
homozygosity, interpretation of the vast amount of data
Siggberg et al. BMC Medical Genetics 2012, 13:84 Page 9 of 10
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benefit of using a SNP based platform is the possibility
to detect UPDs; however these are relatively rare
findings.
This study had a limited number of patients, and so it
can only be said that for this study group the optimal
yield was conceived when using a resolution of approxi-
mately 9Kb [2]. Increasing the resolution beyond that
did not confer more diagnoses. It must be emphasized,
however, that a larger patient cohort needs to be studied
in order to draw final conclusions on the added value of
an ultra-high resolution array compared to others. Fur-
thermore, as several reports have shown, some patho-
genic aberrations span only a few exons and for
detecting such small changes the sensitivity of the SNP
6.0 platform is adequate [18]. It is, however a challenge
to filter results correctly and so for diagnostic purposes
the choice of platform needs to be carefully considered.
Patients with developmental disorders of unknown cause
and normal array results may also harbour such small
genomic changes (i.e. mutations and unbalanced rear-
rangements) that are difficult to interpret using microar-
rays and would require higher resolution methods, such
as whole-exome sequencing. Interestingly, a recent study
suggests that 80% of patients with a developmental dis-
order of unknown cause and normal array results can be
diagnosed using whole-exome sequencing [19]. Only the
future can tell.Availability of supporting data
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